gptkbp:instanceOf
|
gptkb:biotechnology
|
gptkbp:alsoKnownAs
|
gptkb:F._Hoffmann-La_Roche_AG
|
gptkbp:CEO
|
gptkb:Thomas_Schinecker
|
gptkbp:chairman
|
gptkb:Christoph_Franz
|
gptkbp:competitor
|
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
gptkb:Sanofi
gptkb:Novartis
GlaxoSmithKline
|
gptkbp:country
|
gptkb:Switzerland
|
gptkbp:dividendPaying
|
Annual
|
gptkbp:focusArea
|
Neuroscience
Oncology
Immunology
Infectious diseases
Ophthalmology
|
gptkbp:foundedIn
|
1896
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
gptkbp:headquartersLocation
|
gptkb:Basel,_Switzerland
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche Group
|
gptkbp:industry
|
Pharmaceuticals
Diagnostics
|
gptkbp:ISIN
|
CH0012032048
|
gptkbp:languageOfService
|
gptkb:French
gptkb:German
gptkb:Italian
English
|
gptkbp:listedOn
|
gptkb:SIX_Swiss_Exchange
|
gptkbp:logo
|
Roche logo.svg
|
gptkbp:marketCap
|
over CHF 200 billion
|
gptkbp:memberOf
|
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
gptkbp:notableAcquisition
|
gptkb:Foundation_Medicine_(2018)
gptkb:Genentech_(2009)
Flatiron Health (2018)
Spark Therapeutics (2019)
|
gptkbp:numberOfEmployees
|
over 100,000
|
gptkbp:parentCompany
|
gptkb:Genentech
gptkb:Foundation_Medicine
gptkb:Chugai_Pharmaceutical
gptkb:Ventana_Medical_Systems
|
gptkbp:product
|
gptkb:Actemra
gptkb:Avastin
gptkb:Herceptin
gptkb:MabThera
gptkb:Ocrevus
gptkb:Perjeta
gptkb:Rituxan
gptkb:Tamiflu
gptkb:Tecentriq
gptkb:Xeloda
gptkb:Cobas_Diagnostics
|
gptkbp:publiclyTraded
|
Yes
|
gptkbp:rank
|
gptkb:Fortune_Global_500
|
gptkbp:revenue
|
CHF 63.3 billion (2023)
|
gptkbp:slogan
|
Doing now what patients need next
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
gptkbp:stockSymbol
|
gptkb:ROG
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Chugai_Pharmaceutical
|
gptkbp:type
|
Aktiengesellschaft (AG)
|
gptkbp:website
|
https://www.roche.com/
|
gptkbp:bfsParent
|
gptkb:Roche_Diagnostics
|
gptkbp:bfsLayer
|
6
|